Registry for people with generalized myasthenia gravis on Alexion treatment
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study is a registry, meaning it collects health and disease information from people with generalized myasthenia gravis (gMG) who are receiving Alexion C5 “inhibition” therapies. Your data can help researchers better understand real-world outcomes and disease patterns over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have generalized myasthenia gravis (gMG).
- You are currently being treated with an Alexion C5 inhibition therapy (C5IT), such as Soliris or Ultomiris (or you were previously on them and stopped).
- You can sign informed consent and follow the study rules.
- You have past records of your gMG symptoms and severity, like MG-ADL scores and MGFA class.
- You are not currently enrolled in another Alexion-sponsored interventional gMG treatment trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called IMVT-1402 to see if it improves symptoms in people with generalized myasthenia gravis (gMG). If you have mild to severe gMG and are looking for new treatment options, this study may be a fit.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This study follows patients with generalized myasthenia gravis (a condition where muscles weaken over time) who have specific antibodies and are being treated with rozanolixizumab, a medication that helps reduce symptom severity. Researchers will monitor how symptoms change in real-world settings.
This study tests a new drug called SHR-2173 to help people with generalized myasthenia gravis (a condition where muscles weaken because the immune system blocks communication between nerves and muscles). The drug is designed to work with treatments you're already taking to improve muscle strength and reduce symptoms.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial is a global registry for people with myasthenia gravis (MG). It collects information to help researchers better understand MG and improve care.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.